Life Sciences Firm Avacta To Sell Diagnostics Biz For £12.9M
London-listed Avacta Therapeutics said Friday it has agreed to sell a diagnostics business and its subsidiaries for £12.9 million ($16.6 million) after a "very disappointing" venture into diagnostics, as it continues...To view the full article, register now.
Already a subscriber? Click here to view full article